

A decade of optimizing drug development for rare neuromuscular disorders through TACT

Kathryn R. Wagner¹, Annamaria De Luca², Didier Caizergues³, James Dowling⁴, Nathalie Goemans⁵, Heather Gordish-Dressman⁶, Miranda D. Grounds⁷, Michael Kelly⁸, Anna Mayhew⁹, Elizabeth M. McNally¹⁰, Tracey Zoetis¹¹, Joanne Lee⁹, Cathy Turner⁹, Dominic J. Wells¹², Cristina Csimma¹³ and Volker Straub⁹

¹ Center for Genetic Muscle Disorders, Kennedy Krieger Institute and the Departments of Neurology and Neuroscience, Johns Hopkins School of Medicine, Baltimore, Maryland 21205, USA

² Unit of Pharmacology, Department of Pharmacy – Drug Sciences, University of Bari Aldo Moro, Bari, Italy

³ Genethon, Evry, France

⁴ Division of Neurology and Program for Genetics and Genome Biology, Hospital for Sick Children, Toronto, Ontario, Canada M5G 1X8

⁵ University Hospitals Leuven, Dept. of Child Neurology, Leuven, Belgium

⁶ Division of Biostatistics, Children's National Health System, Washington, DC 20010, USA

⁷ School of Human Sciences, the University of Western Australia, Perth, Western Australia, Australia.

⁸ MyoTherix Inc., 2600 Tenth Street, Berkeley, CA 94710, USA

⁹ John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK


¹⁰ Center for Genetic Medicine, Northwestern University Feinberg School of Medicine, Chicago IL 60611 USA

¹¹ SciLucent, LLC, Herndon, VA 20170, USA

¹² Department of Comparative Biomedical Sciences, Royal Veterinary College, London NW1 0TU, UK

¹³ Csimma LLC, Lincoln, MA 01773, USA

<https://doi.org/10.1038/d41573-019-00199-1>



Supplementary Figure 1 | **Status of compounds in development following TACT review.**